82.JPG)
Global Minimal Residual Disease Market Size is valued at USD 1.4 Bn in 2024 and is predicted to reach USD 4.6 Bn by the year 2034 at a 12.8% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
The sophisticated nature of MRD detection methods, including next-generation sequencing (NGS), flow cytometry, and polymerase chain reaction (PCR), present challenges Minimal residual disease, also known as measurable residual disease or MRD, refers to the preclinical stages of diseases such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and multiple myeloma (MM). After treatment, the cancer cells that remain in the body are referred to as a minimal residual disease. These cancer cells are undetected by imaging or physical exams, but sophisticated laboratory tests can discover them. The minimal residual disease is an essential indicator of disease progression and therapy response. The growing importance of the test is expected to drive growth in the worldwide minimum residual disease market in the coming years.
The global incidence of cancer has increased dramatically, which is projected to play a vital role in expanding the global minimal residual illness market. Patients are expected to see more precision in treatment using novel technology. These factors are likely to have an impact on growth. Furthermore, favorable government and private-sector initiatives for developing and adopting NGS technologies, technological advancements in cloud computing and data integration, and the availability of a technologically advanced healthcare research framework are all stimulating market growth. Additionally, the improved regulatory and reimbursement landscape for NGS-based diagnostic tests and increased genome mapping initiatives will fuel market expansion throughout the forecast period.
The minimal residual disease market is segmented on the product, technology, application and end user. Based on product, the minimal residual disease market is divided into assay kits & reagents, instruments. Based on the technology, the minimal residual disease market is divided into polymerase chain reaction, next-generation sequencing, flow cytometry, and other technologies. Based on the Application, the minimal residual disease market is segmented into hematological malignancies, lymphoma, solid tumors, multiple myeloma, and other applications. Based on the end user, the minimal residual disease market is segmented into hospitals & specialty clinics, diagnostic laboratories, academic & research institutes, and other end users.
Based on product, the minimal residual disease market is divided into assay kits & reagents, instruments. Among these, The Assay Kits & Reagents segment leads the MRD detection market due to its frequent and recurring use, as each test requires fresh reagents and assay kits. This segment benefits from the growing demand for repeat testing to monitor MRD levels during and after treatment, making it essential for effective disease management. Additionally, the expanding use of MRD detection in personalized medicine and clinical trials further fuels the demand for these consumables. In contrast, instruments such as flow cytometers and PCR machines represent a smaller yet stable market share, primarily driven by infrastructure investment rather than test volume.
Based on the technology, the minimal residual disease market is divided into polymerase chain reaction, next-generation sequencing, flow cytometry, and other technologies. Among these, the Polymerase Chain Reaction (PCR) segment has traditionally dominated the MRD detection market due to its widespread use, high specificity, and cost-effectiveness in routine clinical monitoring. However, Next-Generation Sequencing (NGS) is emerging as the fastest-growing segment, driven by its ultra-high sensitivity and ability to detect a broad spectrum of genetic alterations, making it increasingly favored in clinical trials and personalized treatment approaches. Flow cytometry also holds a significant share, especially in acute leukemias, offering rapid and relatively affordable results, though with lower sensitivity.
The North American minimal residual disease market is expected to register the highest market share in revenue shortly. The rising prevalence of blood malignancies and the increased investment in MRD research by government and private groups have grown healthcare affordability in the United States and the rise in knowledge and awareness among individuals in this region. In addition, Asia Pacific is projected to grow rapidly in the global minimal residual disease market due to government initiatives and large-scale genome sequencing studies funding to develop targeted treatments to contribute to market growth. Furthermore, the existence of key organizations and industries and the quick spread of paternity testing, genealogy, and personal health awareness drive market growth in this area over the forecast period.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 1.4 Bn |
|
Revenue Forecast In 2034 |
USD 4.6 Bn |
|
Growth Rate CAGR |
CAGR of 12.8% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn,and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Product, Technology, Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ; France; Italy; Spain; South Korea; South East Asia; |
|
Competitive Landscape |
F. Hoffmann-La Roche Ag, Laboratory Corporation of America Holdings, Guardant Health, Inc, Sysmex Corporation, NEOGENOMICS Laboratories, MOLECULARMD, Adaptive Biotechnologies, ARCHERDX, Bio-Rad Laboratories, Inc, Natera, Inc, OPKO Health, Inc, GENETRON Health, Quest Diagnostics, Inc, ASURAGEN, Inc, INVIVOSCRIBE, Inc, Arup Laboratories Inc, Mission Bio, Inc, ERGENTIS B.V |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Minimal Residual Disease Market Snapshot
Chapter 4. Global Minimal Residual Disease Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Minimal Residual Disease Market Industry Trends
4.10. Global Minimal Residual Disease Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Minimal Residual Disease Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. Market Share by Product, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. Assay Kits & Reagents
5.2.2. Instruments
Chapter 6. Minimal Residual Disease Market Segmentation 2: By Technology, Estimates & Trend Analysis
6.1. Market Share by Technology, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Technology:
6.2.1. Polymerase Chain Reaction
6.2.2. Next-Generation Sequencing
6.2.3. Flow Cytometry
6.2.4. Other Technologies
Chapter 7. Minimal Residual Disease Market Segmentation 3: By Application, Estimates & Trend Analysis
7.1. Market Share by Application, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
7.2.1. Hematological Malignancies
7.2.1.1. Leukemia
7.2.1.1.1. Myeloid Leukemia
7.2.1.1.2. Lymphocytic Leukemia
7.2.1.1.3. Other Leukemias
7.2.1.2. Lymphoma
7.2.1.2.1. Non-Hodgkin Lymphoma
7.2.1.2.2. Hodgkin Lymphoma
7.2.2. Solid Tumors
7.2.3. Multiple Myeloma
7.2.4. Other Applications
Chapter 8. Minimal Residual Disease Market Segmentation 3: By End User, Estimates & Trend Analysis
8.1. Market Share by End User, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End User:
8.2.1. Hospitals & Specialty Clinics
8.2.2. Diagnostic Laboratories
8.2.3. Academic & Research Institutes
8.2.4. Other End Users
Chapter 9. Minimal Residual Disease Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Minimal Residual Disease Market, Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.2.3. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.2.4. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.2.5. North America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.3. Europe
9.3.1. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.3.3. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.3.4. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.3.5. Europe Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.4. Asia Pacific
9.4.1. Asia Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.4.3. Asia Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.4.4. Asia Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.4.5. Asia Pacific Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.5. Latin America
9.5.1. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.5.3. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.5.4. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.5.5. Latin America Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.6.3. Middle East & Africa Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2021-2034
9.6.4. Middle East & Africa Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.6.5. Middle East & Africa Minimal Residual Disease Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. F. Hoffmann-La Roche Ag
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service Overview
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Laboratory Corporation Of America Holdings
10.2.3. Guardant Health, Inc.
10.2.4. Sysmex Corporation
10.2.5. NEOGENOMICS Laboratories
10.2.6. MOLECULARMD (A Subsidiary Of Icon Plc)
10.2.7. Adaptive Biotechnologies
10.2.8. ARCHERDX (Invitae Corporation)
10.2.9. Bio-Rad Laboratories, Inc.
10.2.10. Natera, Inc.
10.2.11. OPKO Health, Inc.
10.2.12. GENETRON Health
10.2.13. Quest Diagnostics, Inc.
10.2.14. ASURAGEN, Inc.
10.2.15. INVIVOSCRIBE, Inc.
10.2.16. Arup Laboratories Inc.
10.2.17. Mission Bio, Inc.
10.2.18. CERGENTIS B.V.
Minimal Residual Disease Market By Product
Minimal Residual Disease Market By Technology
Minimal Residual Disease Market By Application
Minimal Residual Disease Market By End User
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
